Skip to content

Lung Cancer Blog

Everything about lung cancer is here.

Menu
  • Home
  • About Us
  • Lung Cancer
    • Lung Cancer News
    • Causes of Lung Cancer
    • Lung Cancer Symptoms
    • Types of Lung Cancer
    • Stages of Lung Cancer
    • Lung Cancer Treatment
    • Lung Cancer Drugs
    • Lung Cancer In Ayurveda
    • Chinese Herbs For Lung Cancer
  • Researches
  • Studies
  • Stories
  • Sitemap
  • Contact Us
Menu
Lung Cancer

Yale Cancer Center Study Shows Long-Term Survival Benefits for Lung Cancer Patients

Posted on February 24, 2020
Post Views: 679

Lung CancerAs per the global study led by Yale Cancer Center, a tiny amount of biomarker known as PD-L1 can predict long-term survival benefits from pembrolizumab. Pembrolizumab (Keytruda) is one of the first inhibitors to be used in the treatment for lung cancer. These recent findings have been published online in the Journal of Clinical Oncology. The findings come from phase III Keynote-010 clinical trial which was conducted in 202 academic centers. The study included patients who have previously been treated unsuccessfully with chemotherapy for stage 3 or 4 non-small cell lung cancer.

In this study, the researchers compared the use of pembrolizumab in 690 patients to treat docetaxel chemotherapy in 343 patients. Out of 690 patients, 79 patients who received two years of pembrolizumab, overall survival rate was 99% one year after discontinuing treatment. The investigators estimate that 75% of NSCLC patients express PD-L1 protein on their cancer cells. Within this group, up to 25% express a high amount.

“The response that we have seen from pembrolizumab, in a subset of patients’ years after treatment ended, is remarkable, especially since their chemotherapy had initially failed,” said Roy S.Herbst, chief of medical oncology at Yale Cancer Center. Some patients whose cancer recurred after an initial two years of treatment responded to pembrolizumab when the drug was offered again, he added.

Keytruda (Pembrolizumab)Herbst said, “It is too soon to say that pembrolizumab is a potential cure for a substantial number of patients whose tumors express PD-L1, and we know that it doesn’t work for all patients, but, the agent remains very, very promising. The majority of patients who completed two years of treatment remain in remission, and those who had recurrence could be retreated with pembrolizumab at the time of progression and still achieve disease control.”

Pembrolizumab is first checkpoint inhibitor for testing the ability of biomarker to determine disease control outcomes. With this study, there’s hope for finding the best way for use of pembrolizumab for treating lung cancer patients.

 

The information shared in this blog is for educational purposes only.

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on Threads (Opens in new window) Threads
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on Tumblr (Opens in new window) Tumblr
  • Click to share on Pocket (Opens in new window) Pocket
  • Click to share on Telegram (Opens in new window) Telegram

Like this:

Like Loading...

Subscribe Us

Popular Articles

  • Lung Cancer Treatment in Ayurveda (7,324)
  • Lung Cancer: Symptoms and Treatment (5,655)
  • What is Non-Small-Cell Lung Cancer? (5,551)

Recent Comments

  • Lung Cancer on New Study To Help Advance Research In Lung Cancer
  • Laurie B Grimes on New Study To Help Advance Research In Lung Cancer
  • Lung Cancer on Asbestos and Lung Cancer – What’s The Link?

Recent Articles

  • Study: Wildfire Smoke Exposure Affects Lung Cancer Survival June 2, 2025
  • Predicting Lung Cancer Risk with AI based Deep Learning Model May 26, 2025
  • FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC May 19, 2025
  • Heart-Sparing Technique in Lung Cancer Radiotherapy May 12, 2025
  • Origins of Common Lung Cancer Linked to Smoking Discovered May 5, 2025

Lung Cancer Blog

Lung Cancer Blog provides all lung cancer related information for educational purposes.

Disclaimer

Some post may contain affiliate links, purchasing that product not going to cost extra but by your purchase Lung Cancer will get some little commission and that amount will help in surviving this website. So, please don’t hesitate to buy from these affiliate links.

Contact Us

If you have any query or suggestions about our blog, please feel free to email us at  lungcancersymptomsx@gmail.com.

Copyright © 2012 - 2025 Lung Cancer Blog. Wordpress by Vipasha.
  • Privacy Policy
  • About Us
  • Sitemap
  • Contact Us
%d